Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell crawled time : 13:15 save search
Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of Cancer
Published: 2021-11-12 (Crawled : 13:15) - globenewswire.com
CLLS | $2.47 0.41% 0.4% 15K
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
immunotherapy solid tumors therapy car-t cancer ucartmeso preclinical t-cell pre-clinical
SITC Abstract: IGM-7354 is an anti-PD-L1 IgM antibody and IL-15 cytokine fusion that enhances NK and CD8+ T cell proliferation and tumor cytotoxicity plus potently reverses T cell exhaustion
Published: 2021-11-09 (Crawled : 13:15) - igmbio.com
IGMS | $7.41 -8.86% -9.86% 450K
|
Health Technology
|
| O: -4.19%
H: 0.0%
C: 0.0%
antibody t-cell
New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
Published: 2021-10-13 (Crawled : 13:15) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.27%
H: 2.38%
C: 1.07%
t-cell
F-star Therapeutics to Present FS120 Phase 1 Trial-in-Progress Update at ESMO 2021Preclinical Data Indicates a Broad Therapeutic Window for F-star’s First-in-Class Tetravalent Dual T cell Agonist
Published: 2021-09-16 (Crawled : 13:15) - biospace.com/
FSTX | $7.12 0.0% 0
|
Health Technology
|
| O: -0.28%
H: 0.71%
C: -0.43%
phase 1 trial t-cell
MEI Pharma and Kyowa Kirin Announce First Patient Dosed in the Phase 3 COASTAL Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-cell Lymphoma
Published: 2021-08-17 (Crawled : 13:15) - biospace.com/
MEIP | $3.25 -1.81% 2.07% 12K
|
Health Technology
|
| O: -1.86%
H: 1.89%
C: 0.38%
phase 3 t-cell
ImmunityBio Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19
Published: 2021-07-14 (Crawled : 13:15) - biospace.com/
IBRX | $4.91 -6.3% -6.5% 2K
|
Manufacturing
|
| O: 0.77%
H: 1.35%
C: -5.32%
covid phase 1 vaccine trial t-cell authorized africa
ImmunityBio Expands Trials of T-Cell-Based COVID-19 Vaccine Candidate as a ‘Universal Boost’ in Vaccinated Subjects and Receives Approval to Test Intranasal Spray in South Africa
Published: 2021-05-25 (Crawled : 13:15) - nantkwest.com
IBRX | $4.91 -6.3% -6.5% 2K
|
Manufacturing
|
| O: 2.23%
H: 2.37%
C: -1.93%
covid nasal spray test vaccine trial approval t-cell africa
Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
Published: 2021-05-18 (Crawled : 13:15) - biospace.com/
MBIO | $0.371 -3.39% -1.05% 210K
|
Health Technology
|
| O: 5.24%
H: 8.64%
C: 5.32%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: -1.41%
H: 12.61%
C: 7.45%
phase 1 trial phase 3 phase 2 car-t t-cell train
Kiromic Announces FDA IND Submission Forty-Five Days before the end of the Second Quarter: First-In-Human, Off-The-Shelf Chimeric PD1 Switch Receptor - Gamma Delta T-cell Therapy
Published: 2021-05-17 (Crawled : 13:15) - biospace.com/
KRBP | $2.5 8.7% -90.21% 830
|
Health Technology
|
| O: -2.94%
H: 9.25%
C: 8.54%
fda therapy submission t-cell fda ide
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
ZCMD | $1.45 5.84% 49.63% 15M
|
Commercial Services
AULT | $0.2421 -7.7% 45.23% 16M
|
Manufacturing
TPET | $0.3279 -3.56% 28.48% 33M
|
n/a
TIRX | $0.8 65.02% 25.95% 410K
|
VTNR 4 | $1.31 33.78% 25.82% 220K
|
Industrial Services
GDHG | $0.263 21.76% 25.34% 1.3M
|
HOLO | $2.95 31.7% 22.49% 37M
|
MTNB | $0.19 -1.04% 14.58% 950K
|
Health Technology
UMAC | $1.55 0.65% 12.9% 0
|
TAOP | $1.08 13.01% 11.51% 19K
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.